Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Edwards Lifesciences to $75 from $88 and keeps an Equal Weight rating on the shares. The firm notes Edwards Lifesciences reported a Q3 in line with expectations for sales and EPS. While the 2023 guide was maintained, the Q4 guide implies incremental full year impact to sales and EPS of $40M and 5c, respectively, driven by FX.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW:
- EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
- Edwards Lifesciences backs FY23 adjusted EPS $2.50-$2.60, consensus $2.55
- Edwards Lifesciences sees Q4 adjusted EPS 60c-66c, consensus 68c
- Edwards Lifesciences reports Q3 adjusted EPS 59c, consensus 59c
- Edwards Lifesciences options imply 6.8% move in share price post-earnings